Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000730382 | SCV000858113 | pathogenic | not provided | 2017-11-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000011517 | SCV001413795 | pathogenic | Fabry disease | 2019-09-27 | criteria provided, single submitter | clinical testing | This variant has been observed in a family affected with Fabry disease (PMID: 12694230). ClinVar contains an entry for this variant (Variation ID: 10770). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Tyr222*) in the GLA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GLA are known to be pathogenic (PMID: 10666480, 12175777). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV000011517 | SCV002054420 | pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000011517 | SCV000031749 | pathogenic | Fabry disease | 2003-03-01 | no assertion criteria provided | literature only |